Literature DB >> 3921045

The influence of captopril, the nitrates and propranolol on apparent liver blood flow.

A N Shepherd, P C Hayes, M Jacyna, L Morrison, I A Bouchier.   

Abstract

Indocyanine green estimated apparent liver blood flow was measured in normal volunteers following glyceryl trinitrate, propranolol, isosorbide mononitrate and captopril. Glyceryl trinitrate and propranolol significantly reduced apparent liver blood flow. Isosorbide mononitrate did not alter apparent liver blood flow or produce an additional reduction in apparent liver blood flow when combined with propranolol. Captopril did not alter apparent liver blood flow despite a significant fall in mean arterial pressure and rise in plasma renin activity. Captopril and isosorbide mononitrate if shown to reduce portal pressure, do so without a fall in apparent liver blood flow.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921045      PMCID: PMC1463738          DOI: 10.1111/j.1365-2125.1985.tb02659.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Captopril in the treatment of clinical hypertension and cardiac failure.

Authors:  A B Atkinson; J I Robertson
Journal:  Lancet       Date:  1979-10-20       Impact factor: 79.321

Review 2.  Liver blood flow. II. Effects of drugs and hormones on liver blood flow.

Authors:  P D Richardson; P G Withrington
Journal:  Gastroenterology       Date:  1981-08       Impact factor: 22.682

3.  Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin.

Authors:  R Hallemans; R Naeije; P Mols; C Mélot; P Reding
Journal:  Crit Care Med       Date:  1983-07       Impact factor: 7.598

4.  Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose.

Authors:  R D Magorien; D W Triffon; C E Desch; W H Bay; D V Unverferth; C V Leier
Journal:  Ann Intern Med       Date:  1981-07       Impact factor: 25.391

5.  Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects.

Authors:  J Feely
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

6.  Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.

Authors:  V Arroyo; J Bosch; M Mauri; F Ribera; F Navarro-López; J Rodés
Journal:  Eur J Clin Invest       Date:  1981-06       Impact factor: 4.686

7.  Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers.

Authors:  A N Shepherd; B C Campbell; J L Reid
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

8.  Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension.

Authors:  R J Groszmann; D Kravetz; J Bosch; M Glickman; J Bruix; J Bredfeldt; H O Conn; J Rodes; E H Storer
Journal:  Hepatology       Date:  1982 Nov-Dec       Impact factor: 17.425

9.  Reduction of liver blood flow and propranolol metabolism by cimetidine.

Authors:  J Feely; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

10.  Propranolol--a medical treatment for portal hypertension?

Authors:  D Lebrec; O Nouel; M Corbic; J P Benhamou
Journal:  Lancet       Date:  1980-07-26       Impact factor: 79.321

View more
  8 in total

1.  Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.

Authors:  H Y Pan; J Triscari; A R DeVault; S A Smith; D Wang-Iverson; B N Swanson; D A Willard
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

3.  The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure.

Authors:  K Dickstein; A E Till; T Aarsland; K Tjelta; A M Abrahamsen; K Kristianson; H J Gomez; H Gregg; M Hichens
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

4.  Changes in indocyanine green kinetics after the administration of enalapril to healthy subjects.

Authors:  J Geneve; T Le Dinh; A Brouard; M Bails; J M Segrestaa; C Caulin
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

5.  Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green.

Authors:  P A Soons; A De Boer; A F Cohen; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

6.  The influence of nifedipine and captopril on liver blood flow in healthy subjects.

Authors:  J Burggraaf; R C Schoemaker; J M Kroon; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

7.  Specificity of different organic nitrates to elicit NO formation in rabbit vascular tissues and organs in vivo.

Authors:  A Mülsch; A Bara; P Mordvintcev; A Vanin; R Busse
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

8.  Atrial natriuretic peptides: reproducibility of renal effects and response of liver blood flow.

Authors:  J Biollaz; B Waeber; J Nussberger; M Porchet; F Brunner-Ferber; E S Otterbein; H J Gomez; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.